{"fetched":"2026-10-01","decisions":[{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, neoadjuvante und adjuvante Kombination mit FLOT-Chemotherapie gefolgt von adjuvanter Monotherapie)","verdict":"Verfahren begonnen","verdictLabel":"Procedure started","date":"2026-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1336/","note":"Neues Anwendungsgebiet: Adenokarzinom des Magens oder des gastroösophagealen Übergangs, neoadjuvante und adjuvante Kombination mit FLOT-Chemotherapie gefolgt von adjuvanter Monotherapie"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – July 2026","verdict":"document","verdictLabel":"Outcomes document","date":"2026-07","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-july-2026","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-07/pbac-web-outcomes-07-2026-v1.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – May 2026 Intracycle meeting","verdict":"document","verdictLabel":"Outcomes document","date":"2026-05","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-may-2026-intracycle-meeting","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-05/pbac-web-outcomes-05-2026.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – March 2026","verdict":"document","verdictLabel":"Outcomes document","date":"2026-03","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-march-2026","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2026-03/pbac-web-outcomes-03-2026-v3.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"pembrolizumab","product":"Pembrolizumab","brand":"Keytruda","title":"Pembrolizumab (Neues Anwendungsgebiet: Resezierbares lokal fortgeschrittenes Plattenepithelkarzinom der Kopf-Hals-Region, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Kombination mit Strahlentherapie mit oder ohne begleitende Cisplatin-Therapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-12-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1288/","note":"Neues Anwendungsgebiet: Resezierbares lokal fortgeschrittenes Plattenepithelkarzinom der Kopf-Hals-Region, PD-L1-Expression ≥ 1 %, neoadjuvante und adjuvante Therapie, Kombination mit Strahlentherapie mit oder ohne begleitende Cisplatin-Therapie"},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – December 2025 Intracycle Meeting","verdict":"document","verdictLabel":"Outcomes document","date":"2025-12","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-december-2025-intracycle-meeting","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-12/pbac-web-outcomes-v2-12-2025.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – November 2025","verdict":"document","verdictLabel":"Outcomes document","date":"2025-11","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-november-2025","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-11/pbac-web-outcomes-11-2025-v2.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"PBAC","country":"Australia","product":"All items considered at the meeting","title":"Recommendations made by the PBAC – September 2025 Intracycle meeting","verdict":"document","verdictLabel":"Outcomes document","date":"2025-09","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-september-2025","documentUrl":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2025-09/pbac-web-outcomes-09-2025v2.pdf","note":"PBAC publishes outcomes as PDF; open the document for product-level recommendations."},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, nicht fortgeschrittenes Stadium, nach platinbasierter Radiochemotherapie, Monotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1201/","note":"Neues Anwendungsgebiet: kleinzelliges Lungenkarzinom, nicht fortgeschrittenes Stadium, nach platinbasierter Radiochemotherapie, Monotherapie"},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom (MIBC), neoadjuvante/adjuvante Therapie nach Zystektomie, Kombination mit Gemcitabin und Cisplatin)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1247/","note":"Neues Anwendungsgebiet: Muskelinvasives Blasenkarzinom (MIBC), neoadjuvante/adjuvante Therapie nach Zystektomie, Kombination mit Gemcitabin und Cisplatin"},{"body":"G-BA","country":"Germany","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab (Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR/ALK-negativ, neoadjuvante/adjuvante Therapie, Kombination mit platinbasierter Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-08-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1207/","note":"Neues Anwendungsgebiet: nicht-kleinzelliges Lungenkarzinom, EGFR/ALK-negativ, neoadjuvante/adjuvante Therapie, Kombination mit platinbasierter Chemotherapie"},{"body":"G-BA","country":"Germany","drugId":"pembrolizumab","product":"Pembrolizumab","brand":"Keytruda","title":"Pembrolizumab (Neues Anwendungsgebiet: Malignes Pleuramesotheliom, nicht-epitheloid, Erstlinie, Kombination mit Pemetrexed und Platin-Chemotherapie)","verdict":"Verfahren abgeschlossen","verdictLabel":"Verfahren abgeschlossen","date":"2025-05-01","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1203/","note":"Neues Anwendungsgebiet: Malignes Pleuramesotheliom, nicht-epitheloid, Erstlinie, Kombination mit Pemetrexed und Platin-Chemotherapie"},{"body":"NICE","country":"UK","drugId":"pluvicto","product":"Lutetium-177 vipivotide tetraxetan","brand":"Pluvicto","title":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments","verdict":"not recommended","verdictLabel":"Not recommended","date":"2023-11-15","url":"https://www.nice.org.uk/guidance/ta930","note":"PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (VISION)"},{"body":"NICE","country":"UK","drugId":"y-90-resin-microspheres","product":"Yttrium-90 resin microspheres","brand":"SIR-Spheres","title":"Selective internal radiation therapies for treating hepatocellular carcinoma","verdict":"mismatch","verdictLabel":"TA page does not name this product","date":"2021-03-31","updated":"2024-07-03","url":"https://www.nice.org.uk/guidance/ta688","note":"Curated status optimised; the cited TA number may be wrong or renumbered"},{"body":"NICE","country":"UK","drugId":"y-90-glass-microspheres","product":"Yttrium-90 glass microspheres","brand":"TheraSphere","title":"Selective internal radiation therapies for treating hepatocellular carcinoma","verdict":"mismatch","verdictLabel":"TA page does not name this product","date":"2021-03-31","updated":"2024-07-03","url":"https://www.nice.org.uk/guidance/ta688","note":"Curated status optimised; the cited TA number may be wrong or renumbered"},{"body":"NICE","country":"UK","drugId":"durvalumab","product":"Durvalumab","brand":"Imfinzi","title":"Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2019-05-01","url":"https://www.nice.org.uk/guidance/ta578","note":"Unresectable stage III NSCLC after chemoradiation (PACIFIC)"},{"body":"NICE","country":"UK","drugId":"lutathera","product":"Lutetium-177 dotatate","brand":"Lutathera","title":"Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours","verdict":"recommended","verdictLabel":"Recommended","date":"2018-08-29","url":"https://www.nice.org.uk/guidance/ta539","note":"Unresectable or metastatic, progressive, well-differentiated somatostatin receptor-positive GEP-NETs"},{"body":"NICE","country":"UK","drugId":"pembrolizumab","product":"Pembrolizumab","brand":"Keytruda / Keytruda Qlex (SC)","title":"Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer","verdict":"optimised","verdictLabel":"Recommended (optimised)","date":"2018-07-18","url":"https://www.nice.org.uk/guidance/ta531","note":"Untreated PD-L1 ≥50% metastatic NSCLC (2-year stopping rule)"},{"body":"NICE","country":"UK","drugId":"sorafenib","product":"Sorafenib","brand":"Nexavar","title":"Sorafenib for treating advanced hepatocellular carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2017-09-06","url":"https://www.nice.org.uk/guidance/ta474","note":"Advanced HCC (Child-Pugh A)"},{"body":"NICE","country":"UK","drugId":"cabozantinib","product":"Cabozantinib","brand":"Cabometyx","title":"Cabozantinib for previously treated advanced renal cell carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2017-08-09","url":"https://www.nice.org.uk/guidance/ta463","note":"Advanced RCC after VEGF-targeted therapy"},{"body":"NICE","country":"UK","drugId":"everolimus","product":"Everolimus","brand":"Afinitor","title":"Everolimus for advanced renal cell carcinoma after previous treatment","verdict":"recommended","verdictLabel":"Recommended","date":"2017-02-22","url":"https://www.nice.org.uk/guidance/ta432","note":"Advanced renal cell carcinoma after previous treatment"},{"body":"NICE","country":"UK","drugId":"radium-223","product":"Radium-223 dichloride","brand":"Xofigo","title":"Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases","verdict":"optimised","verdictLabel":"Recommended (optimised)","date":"2016-09-28","url":"https://www.nice.org.uk/guidance/ta412","note":"Hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases, only after docetaxel or where docetaxel is unsuitable"},{"body":"NICE","country":"UK","drugId":"cabazitaxel","product":"Cabazitaxel","brand":"Jevtana","title":"Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel","verdict":"recommended","verdictLabel":"Recommended","date":"2016-05-25","updated":"2016-08-24","url":"https://www.nice.org.uk/guidance/ta391","note":"Metastatic hormone-relapsed prostate cancer after docetaxel"},{"body":"NICE","country":"UK","drugId":"olaparib","product":"Olaparib","brand":"Lynparza","title":"Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy","verdict":"superseded","verdictLabel":"Superseded by newer guidance","date":"2016-01-27","url":"https://www.nice.org.uk/guidance/ta381","note":"Maintenance for relapsed platinum-sensitive BRCA-mutated ovarian cancer"},{"body":"NICE","country":"UK","drugId":"enzalutamide","product":"Enzalutamide","brand":"Xtandi","title":"Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen","verdict":"recommended","verdictLabel":"Recommended","date":"2014-07-23","url":"https://www.nice.org.uk/guidance/ta316","note":"Metastatic castration-resistant prostate cancer after docetaxel"},{"body":"NICE","country":"UK","drugId":"abiraterone","product":"Abiraterone acetate","brand":"Zytiga (generic)","title":"Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen","verdict":"recommended","verdictLabel":"Recommended","date":"2012-06-27","updated":"2016-07-27","url":"https://www.nice.org.uk/guidance/ta259","note":"Metastatic castration-resistant prostate cancer after docetaxel"},{"body":"NICE","country":"UK","drugId":"sunitinib","product":"Sunitinib","brand":"Sutent","title":"Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma","verdict":"recommended","verdictLabel":"Recommended","date":"2009-03-25","url":"https://www.nice.org.uk/guidance/ta169","note":"First-line advanced or metastatic RCC"},{"body":"NICE","country":"UK","drugId":"rituximab","product":"Rituximab","brand":"Rituxan / MabThera (and biosimilars)","title":"Rituximab for aggressive non-Hodgkin's lymphoma","verdict":"recommended","verdictLabel":"Recommended","date":"2003-09-24","url":"https://www.nice.org.uk/guidance/ta65","note":"Aggressive (diffuse large B-cell) non-Hodgkin lymphoma with CHOP"}],"errors":[],"bodies":{"NICE":{"name":"National Institute for Health and Care Excellence","country":"United Kingdom (England and Wales)","url":"https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance","method":"Each TA cited in coverage-uk.ts is fetched to confirm title, publication date and withdrawal status","checked":16,"ok":16,"failed":0},"G-BA":{"name":"Gemeinsamer Bundesausschuss","country":"Germany","url":"https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/","method":"First 8 pages of the early benefit assessment register, matched to corpus products by active substance","checked":8,"ok":8,"failed":0},"PBAC":{"name":"Pharmaceutical Benefits Advisory Committee","country":"Australia","url":"https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes","method":"Latest meetings listed with links to the outcome documents (PDF; verdicts not extracted)","checked":1,"ok":1,"failed":0,"note":"6 most recent meetings listed"}}}